000241161 001__ 241161
000241161 005__ 20240229145758.0
000241161 0247_ $$2doi$$a10.1097/RLI.0000000000000940
000241161 0247_ $$2pmid$$apmid:36729753
000241161 0247_ $$2ISSN$$a0020-9996
000241161 0247_ $$2ISSN$$a1536-0210
000241161 037__ $$aDKFZ-2023-00269
000241161 041__ $$aEnglish
000241161 082__ $$a610
000241161 1001_ $$aPreisner, Fabian$$b0
000241161 245__ $$aSimultaneous Multislice Accelerated TSE for Improved Spatiotemporal Resolution and Diagnostic Accuracy in Magnetic Resonance Neurography: A Feasibility Study.
000241161 260__ $$a[Erscheinungsort nicht ermittelbar]$$bOvid$$c2023
000241161 3367_ $$2DRIVER$$aarticle
000241161 3367_ $$2DataCite$$aOutput Types/Journal article
000241161 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1681886515_17224
000241161 3367_ $$2BibTeX$$aARTICLE
000241161 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000241161 3367_ $$00$$2EndNote$$aJournal Article
000241161 500__ $$a2023 May 1;58(5):363-371
000241161 520__ $$aThis study aims to evaluate the utility of simultaneous multislice (SMS) acceleration for routine magnetic resonance neurography (MRN) at 3 T.Patients with multiple sclerosis underwent MRN of the sciatic nerve consisting of a standard fat-saturated T2-weighted turbo spin echo (TSE) sequence using integrated parallel acquisition technique (PAT2) acceleration and 2 T2 TSE sequences using a combination of PAT-SMS acceleration (1) to reduce scan time (PAT2-SMS2; SMS-TSEFAST) and (2) for time neutral increase of in-plane resolution (PAT1-SMS2; SMS-TSEHR). Acquisition times were 5:29 minutes for the standard T2 TSE, 3:12 minutes for the SMS-TSEFAST, and 5:24 minutes for the SMS-TSEHR. Six qualitative imaging parameters were analyzed by 2 blinded readers using a 5-point Likert scale and T2 nerve lesions were quantified, respectively. Qualitative and quantitative image parameters were compared, and both interrater and intrarater reproducibility were statistically assessed. In addition, signal-to-noise ratio/contrast-to-noise ratio (CNR) was obtained in healthy controls using the exact same imaging protocol.A total of 15 patients with MS (mean age ± standard deviation, 38.1 ± 11 years) and 10 healthy controls (mean age, 29.1 ± 7 years) were enrolled in this study. CNR analysis was highly reliable (intraclass correlation coefficient, 0.755-0.948) and revealed a significant CNR decrease for the sciatic nerve for both SMS protocols compared with standard T2 TSE (SMS-TSEFAST/SMS-TSEHR, -39%/-55%; P ≤ 0.01). Intrarater and interrater reliability of qualitative image review was good to excellent (κ: 0.672-0.971/0.617-0.883). Compared with the standard T2 TSE sequence, both SMS methods were shown to be superior in reducing pulsatile flow artifacts (P < 0.01). Ratings for muscle border sharpness, detailed muscle structures, nerve border sharpness, and nerve fascicular structure did not differ significantly between the standard T2 TSE and the SMS-TSEFAST (P > 0.05) and were significantly better for the SMS-TSEHR than for standard T2 TSE (P < 0.001). Muscle signal homogeneity was mildly inferior for both SMS-TSEFAST (P > 0.05) and SMS-TSEHR (P < 0.001). A significantly higher number of T2 nerve lesions were detected by SMS-TSEHR (P ≤ 0.01) compared with the standard T2 TSE and SMS-TSEFAST, whereas no significant difference was observed between the standard T2 TSE and SMS-TSEFAST.Implementation of SMS offers either to substantially reduce acquisition time by over 40% without significantly impeding image quality compared with the standard T2 TSE or to increase in-plane resolution for a high-resolution approach and improved depiction of T2 nerve lesions while keeping acquisition times constant. This addresses the specific needs of MRN by providing different imaging approaches for 2D clinical MRN.
000241161 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000241161 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000241161 7001_ $$aHayes, Jennifer C$$b1
000241161 7001_ $$aCharlet, Tobias$$b2
000241161 7001_ $$aCarinci, Flavio$$b3
000241161 7001_ $$0P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f$$aHielscher, Thomas$$b4$$udkfz
000241161 7001_ $$aSchwarz, Daniel$$b5
000241161 7001_ $$aVollherbst, Dominik F$$b6
000241161 7001_ $$aBreckwoldt, Michael O$$b7
000241161 7001_ $$aJesser, Jessica$$b8
000241161 7001_ $$aHeiland, Sabine$$b9
000241161 7001_ $$aBendszus, Martin$$b10
000241161 7001_ $$aHilgenfeld, Tim$$b11
000241161 773__ $$0PERI:(DE-600)2041543-6$$a10.1097/RLI.0000000000000940$$gVol. Publish Ahead of Print$$n5$$p363-371$$tInvestigative radiology$$v58$$x0020-9996$$y2023
000241161 909CO $$ooai:inrepo02.dkfz.de:241161$$pVDB
000241161 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000241161 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000241161 9141_ $$y2022
000241161 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2022-11-29
000241161 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-29
000241161 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-29
000241161 915__ $$0StatID:(DE-HGF)0410$$2StatID$$aAllianz-Lizenz$$d2023-10-24$$wger
000241161 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-24
000241161 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-24
000241161 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-24
000241161 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-24
000241161 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-10-24
000241161 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-24
000241161 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bINVEST RADIOL : 2022$$d2023-10-24
000241161 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-24
000241161 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bINVEST RADIOL : 2022$$d2023-10-24
000241161 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lC060 Biostatistik$$x0
000241161 980__ $$ajournal
000241161 980__ $$aVDB
000241161 980__ $$aI:(DE-He78)C060-20160331
000241161 980__ $$aUNRESTRICTED